"Sympatholytics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.
| Descriptor ID |
D013565
|
| MeSH Number(s) |
D27.505.696.663.050.850
|
| Concept/Terms |
Sympatholytics- Sympatholytics
- Sympatholytic Agents
- Agents, Sympatholytic
- Sympatholytic Drugs
- Drugs, Sympatholytic
- Sympathetic-Blocking Agents
- Agents, Sympathetic-Blocking
- Sympathetic Blocking Agents
Sympatholytic Effect- Sympatholytic Effect
- Effect, Sympatholytic
- Sympatholytic Effects
- Effects, Sympatholytic
|
Below are MeSH descriptors whose meaning is more general than "Sympatholytics".
Below are MeSH descriptors whose meaning is more specific than "Sympatholytics".
This graph shows the total number of publications written about "Sympatholytics" by people in this website by year, and whether "Sympatholytics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sympatholytics" by people in Profiles.
-
Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of Resistant and Refractory Hypertension. Circ Res. 2019 03 29; 124(7):1061-1070.
-
Krasnova IN, Betts ES, Dada A, Jefferson A, Ladenheim B, Becker KG, Cadet JL, Hohmann CF. Neonatal dopamine depletion induces changes in morphogenesis and gene expression in the developing cortex. Neurotox Res. 2007 Feb; 11(2):107-30.
-
Lee DC, Womble TA, Mason CW, Jackson IM, Lamango NS, Severs WB, Palm DE. 6-Hydroxydopamine induces cystatin C-mediated cysteine protease suppression and cathepsin D activation. Neurochem Int. 2007 Mar; 50(4):607-18.
-
Lee DC, Close FT, Goodman CB, Jackson IM, Wight-Mason C, Wells LM, Womble TA, Palm DE. Enhanced cystatin C and lysosomal protease expression following 6-hydroxydopamine exposure. Neurotoxicology. 2006 Mar; 27(2):260-76.
-
Mazzio EA, Kolta MG, Reams RR, Soliman KF. Inhibitory effects of cigarette smoke on glial inducible nitric oxide synthase and lack of protective properties against oxidative neurotoxins in vitro. Neurotoxicology. 2005 Jan; 26(1):49-62.
-
Yakubu MA, Pourcyrous M, Randolph MM, Blaho KE, Mandrell TD, Bada HS, Leffler CW. Consequences of maternal cocaine on cerebral microvascular functions in piglets. Brain Res. 2002 Aug 30; 947(2):174-81.
-
Oparil S, Calhoun DA. Hypertension. Dis Mon. 1989 Mar; 35(3):133-232.
-
Kawai Y, Powell A, Arinze IJ. Adrenergic receptors in human liver plasma membranes: predominance of beta 2- and alpha 1-receptor subtypes. J Clin Endocrinol Metab. 1986 May; 62(5):827-32.